These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 30138772)

  • 1. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
    Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
    Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
    [No Abstract]   [Full Text] [Related]  

  • 2. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
    Earl DE; Loochtan AI; Bedlack RS
    Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
    [No Abstract]   [Full Text] [Related]  

  • 3. Pembrolizumab-associated ocular myasthenia gravis.
    Liu Q; Ayyappan S; Broad A; Narita A
    Clin Exp Ophthalmol; 2019 Aug; 47(6):796-798. PubMed ID: 30859689
    [No Abstract]   [Full Text] [Related]  

  • 4. Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody.
    Shirai T; Kiniwa Y; Sato R; Sano T; Nakamura K; Mikoshiba Y; Ohashi N; Sekijima Y; Okuyama R
    Eur J Cancer; 2019 Jan; 106():193-195. PubMed ID: 30528803
    [No Abstract]   [Full Text] [Related]  

  • 5. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
    Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
    Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab-Induced Alopecia Areata.
    Elshimy N; Blakeway E; Mitra A
    Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
    [No Abstract]   [Full Text] [Related]  

  • 7. Acute localised exanthematous pustulosis secondary to pembrolizumab.
    Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
    Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
    [No Abstract]   [Full Text] [Related]  

  • 8. Myasthenia gravis exacerbation associated with pembrolizumab.
    Zhu J; Li Y
    Muscle Nerve; 2016 Sep; 54(3):506-7. PubMed ID: 26802533
    [No Abstract]   [Full Text] [Related]  

  • 9. Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy.
    Onda A; Miyagawa S; Takahashi N; Gochi M; Takagi M; Nishino I; Suzuki S; Oishi C; Yaguchi H
    Intern Med; 2019 Jun; 58(11):1635-1638. PubMed ID: 30713313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
    Arianayagam S; Ieremia E; Matin RN
    Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
    [No Abstract]   [Full Text] [Related]  

  • 11. Pembrolizumab-induced myasthenia gravis: A fatal case report.
    March KL; Samarin MJ; Sodhi A; Owens RE
    J Oncol Pharm Pract; 2018 Mar; 24(2):146-149. PubMed ID: 28147928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
    Algaeed M; Mukharesh L; Heinzelmann M; Kaminski HJ
    Neurology; 2018 Oct; 91(14):e1365-e1367. PubMed ID: 30275130
    [No Abstract]   [Full Text] [Related]  

  • 13. Checkpoint inhibitor myasthenia-like syndrome and myositis associated with extraocular muscle atrophy.
    Ozarczuk TRA; Prentice DA; Kho LK; vanHeerden J
    J Clin Neurosci; 2020 Jan; 71():271-272. PubMed ID: 31889642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII.
    Wada N; Uchi H; Furue M
    J Dermatol; 2017 Oct; 44(10):e240-e241. PubMed ID: 28677843
    [No Abstract]   [Full Text] [Related]  

  • 15. Fatal myasthenia gravis (MG) associated with myositis and myocarditis in a patient with pre-existing MG treated by adjuvant nivolumab for a stage III melanoma.
    Emile J; Cauquil C; Carpentier D; Routier E; Robert C
    Eur J Cancer; 2024 Jul; 205():114098. PubMed ID: 38761774
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treating metastatic melanoma: Risk management].
    Lebbe C; Robert C
    Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
    [No Abstract]   [Full Text] [Related]  

  • 17. [A case of myasthenia gravis and myositis induced by pembrolizumab].
    Noda T; Kageyama H; Miura M; Tamura T; Ito H
    Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.
    Gonzalez NL; Puwanant A; Lu A; Marks SM; Živković SA
    Neuromuscul Disord; 2017 Mar; 27(3):266-268. PubMed ID: 28109638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cascade of immunologic adverse events related to pembrolizumab treatment.
    Dhenin A; Samartzi V; Lejeune S; Seront E
    BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31167767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab.
    Jonsson DI; Pirskanen R; Piehl F
    Neuromuscul Disord; 2017 Jun; 27(6):565-568. PubMed ID: 28433474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.